Stocks Health care AMRX
NASDAQ · Health careAmneal Pharmaceuticals, Inc. (AMRX)
Amneal Pharmaceuticals, Inc. brought in $3.2B of revenue over the twelve months to September 30, 2026, up 8.9% from a year earlier. Net income was $133.3M, a net margin of 4.2%. Operating cash flow minus capital spending left $269.9M of free cash flow in fiscal 2025. At September 30, 2026 it held $157.4M in cash against $2.9B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Amneal Pharmaceuticals, Inc.
- Net worth
- Amneal Pharmaceuticals, Inc. has a market value (market cap) of $7.4B at the latest share price, and shareholders' equity of $531.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $3B (+8.0% year on year), with net income of $72.1M. Over the 12 months to September 30, 2026: revenue $3.2B, net income $133.3M.
- Cash flow
- In fiscal 2025 operations brought in $340M of cash; after $70.1M of capital spending, free cash flow was $269.9M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Amneal Pharmaceuticals, Inc.'s next report is expected around January 12, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Amneal Pharmaceuticals, Inc. does
Amneal Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AMRX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $3B | $72.1M | $0.22 | $269.9M |
| 2024 | $2.8B | -$116.9M | -$0.38 | $243.2M |
| 2023 | $2.4B | -$84M | -$0.48 | $302.4M |
| 2022 | $2.2B | -$270.6M | -$0.86 | $18.7M |
| 2021 | $2.1B | $13.2M | $0.07 | $194.1M |
| 2020 | $2B | $67.8M | $0.61 | $322.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where AMRX ranks in Health care
Dividends
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2020 | n/a | $0 | 0% |
| 2019 | n/a | $0 | n/a |
| 2018 | n/a | $183M | n/a |
| 2017 | n/a | $375.3M | n/a |
| 2016 | n/a | $200.6M | n/a |
Latest SEC filings
What Amneal Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 10% to $862.7M versus the same quarter last year; diluted EPS -$0.06 versus $0.01.
- November 3, 2026
- October 23, 2026Exhibits 8-K/A
- September 3, 2026
- August 12, 2026Activist stake changed SCHEDULE 13D/A
- August 12, 2026Activist stake changed SCHEDULE 13D/A
- August 12, 2026Activist stake changed SCHEDULE 13D/A
- August 10, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 9.9% to $796.2M versus the same quarter last year; diluted EPS $0.18 versus $0.07.
- August 3, 2026
What is AMRX worth? A DCF from its reported cash flow
Insider trades
What the people running Amneal Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $882K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 17, 2026 | Buchi J KevinDirector | Gave as a gift | 20,445 | - |
| September 11, 2026 | Buchi J KevinDirector | Exercised options | 20,445 | $295.4K |
| September 1, 2026 | Boyer Andrew SExecutive Vice President | Gave as a gift | 80,000 | - |
| August 21, 2026 | Boyer Andrew SExecutive Vice President | Gave as a gift | 152,426 | - |
| August 13, 2026 | Kiely JohnDirector | Sold | 50,000 | $882K |
| August 13, 2026 | Kiely JohnDirector | Gave as a gift | 10,000 | - |
| August 12, 2026 | Daly Jason B.EVP, Chief Legal Officer | Sold | 210,000 | $3.7M |
| August 12, 2026 | Shah NikitaExecutive Vice President | Sold | 146,403 | $2.6M |
Who owns AMRX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Tushar Patel13D, may seek influence | 17.6% | August 12, 2026 |
| Chintu Patel13D, may seek influence | 9.4% | August 12, 2026 |
| Chirag Patel13D, may seek influence | 8.4% | August 12, 2026 |
| Akram Mahesh13G, passive | 6.56% | May 14, 2025 |
| Patel Dipan13D, may seek influence | 5.4% | March 26, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 308 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 26,562,093 | +2,042,901 |
| Tpg GP A, LLC | 12,328,767 | 0 |
| Vanguard Portfolio Management LLC | 12,137,727 | +812,794 |
| Rubric Capital Management LP | 10,168,660 | -868,929 |
| Vanguard Capital Management LLC | 7,710,126 | +125,092 |
| State Street Corp | 7,356,977 | +562,275 |
| Dimensional Fund Advisors LP | 5,794,263 | +103,677 |
| Geode Capital Management, LLC | 5,139,449 | +593,401 |
| Assenagon Asset Management S.A. | 4,891,098 | +1,823,737 |
| Nantahala Capital Management, LLC | 4,537,502 | +1,693,394 |
| Morgan Stanley | 4,110,028 | -527,157 |
| Neuberger Berman Group LLC | 3,887,179 | +204,895 |
| Invesco Ltd. | 3,502,000 | +313,341 |
| Nuveen, LLC | 3,324,875 | +81,232 |
| Allspring Global Investments Holdings, LLC | 3,295,533 | +745,961 |
| Goldman Sachs Group Inc | 3,013,961 | +150,101 |
| Charles Schwab Investment Management Inc | 2,147,450 | -36,711 |
| Northern Trust Corp | 1,914,895 | +208,788 |
| Ameriprise Financial Inc | 1,581,869 | -283,332 |
| Westshore Wealth, LLC | 1,366,274 | -7,710 |
Insiders
15 insiders reported holding 82,032,927 shares in total, about $1.75B at the last price.
| Holder | Shares |
|---|---|
| Patel Tushar Bhikhubhai10% owner | 61,341,67861,341,678 held indirectly |
| Patel Chirag K.President & Co-CEO, Director | 7,775,2046,381,734 held indirectly |
| Patel ChintuCo-CEO, Director | 7,770,2556,381,734 held indirectly |
| Patel GautamDirector | 1,927,595283,632 held indirectly |
| Meister Paul MDirector | 832,800 |
| Konidaris TasosExecutive Vice President & CFO | 449,434 |
| George Jeffrey P.Director | 344,614 |
| Nark Ted CDirector | 325,848 |
| Yanai ShlomoDirector | 320,804 |
| Shah NikitaExecutive Vice President | 253,390 |
Questions about AMRX
What does Amneal Pharmaceuticals, Inc. do?
Amneal Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as AMRX. Its shares trade on NASDAQ under the ticker AMRX.
What is Amneal Pharmaceuticals, Inc.'s net worth?
Amneal Pharmaceuticals, Inc. has a market value (market cap) of $7.4B at the latest share price, and shareholders' equity of $531.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Amneal Pharmaceuticals, Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $133.3M on revenue of $3.2B, a net margin of 4.2%.
How much revenue does Amneal Pharmaceuticals, Inc. make?
Over the twelve months to September 30, 2026 Amneal Pharmaceuticals, Inc. reported revenue of $3.2B. That is 8.9% more than a year earlier.
When did Amneal Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Amneal Pharmaceuticals, Inc.'s next earnings report?
Amneal Pharmaceuticals, Inc.'s next report is expected around January 12, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare AMRX with
Follow AMRX
Get an email when Amneal Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Amneal Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.